Relmada Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for pain and related disorders
The company is dedicated to addressing unmet medical needs through its advanced therapeutic candidates, which aim to provide safe and effective alternatives to existing pain management options. By leveraging its expertise in neuroscience and pharmacology, Relmada Therapeutics is working towards advancing novel therapies that enhance the quality of life for patients suffering from chronic pain conditions and other neurological issues.
NEW YORK, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Shift4 Payments, Inc. (NYSEFOUR), Waldencast Plc NASDAQ: WALDNASDAQWALD)(NYSE: RLMDNYSERLMD, and DoubleVerify Holdings, Inc. (NYSE: DVNYSE). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
NEW YORK, Aug. 06, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Shift4 Payments, Inc. (NYSEFOUR), Waldencast Plc NASDAQ: WALDNASDAQWALD)(NYSE: RLMDNYSERLMD, and DoubleVerify Holdings, Inc. (NYSE: DVNYSE). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
NEW YORK, July 26, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Relmada Therapeutics, Inc. (NYSERLMD), Arrival SA NASDAQ: ARVLNASDAQARVL)(NYSE: FMCNYSEFMC, and Viasat, Inc. (NASDAQ: VSATNASDAQ). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
NEW YORK, July 21, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Waldencast Plc (NASDAQWALD), Relmada Therapeutics, Inc. NASDAQ: RLMDNASDAQRLMD)(NYSE: DVNYSEDV, and Castle Biosciences, Inc. (NASDAQ: CSTLNASDAQ). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
NEW YORK, July 16, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Shift4 Payments, Inc. (NYSEFOUR), Waldencast Plc NASDAQ: WALDNASDAQWALD)(NYSE: RLMDNYSERLMD, and DoubleVerify Holdings, Inc. (NYSE: DVNYSE). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
NEW YORK, July 10, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Shift4 Payments, Inc. (NYSEFOUR), Waldencast Plc NASDAQ: WALDNASDAQWALD)(NYSE: CHGGNYSECHGG, and Relmada Therapeutics, Inc. (NYSE: RLMDNYSE). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
NEW YORK, July 05, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Shift4 Payments, Inc. (NYSEFOUR), Waldencast Plc NASDAQ: WALDNASDAQWALD)(NYSE: CHGGNYSECHGG, and Relmada Therapeutics, Inc. (NASDAQ: RLMDNASDAQ). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
NEW YORK, July 01, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Seagate Technology Holdings Plc (NASDAQSTX), Chegg, Inc. NYSE: CHGGNYSECHGG)(NASDAQ: RLMDNASDAQRLMD, and DoubleVerify Holdings, Inc. (NYSE: DVNYSE). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
NEW YORK, June 25, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Relmada Therapeutics, Inc. (NYSERLMD), DoubleVerify Holdings, Inc. NYSE: DVNYSEDV)(NASDAQ: SANMNASDAQSANM, and JinkoSolar Holding Co., Ltd. (NYSE: JKSNYSE). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
NEW YORK, June 19, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Waldencast Plc (NASDAQWALD), Seagate Technology Holdings Plc NASDAQ: STXNASDAQSTX)(NYSE: CHGGNYSECHGG, and Relmada Therapeutics, Inc. (NASDAQ: RLMDNASDAQ). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
NEW YORK, May 19, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Relmada Therapeutics, Inc. (NYSERLMD), and Sanmina Corporation NASDAQ: SANMNASDAQSANM)
NEW YORK, May 14, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fox Corporation (NASDAQ: FOX, FOXA), Cutera, Inc. (NASDAQCUTR), and Relmada Therapeutics, Inc. NYSE: RLMDNYSERLMD)
San Diego, CA -- (SBWIRE) -- 05/11/2023 -- An investigation was announced for investors of Relmada Therapeutics, Inc. (NASDAQRLMD) shares over potential securities laws violations by Relmada Therapeutics, Inc.
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Relmada Therapeutics, Inc. (“Relmada” or “the Company”) (NASDAQRLMD). Investors who purchased Relmada securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/rlmd.
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Relmada Therapeutics, Inc. (“Relmada” or the “Company”) (NYSERLMD) on behalf of Relmada stockholders. Our investigation concerns whether Relmada has violated the federal securities laws and/or engaged in other unlawful business practices.
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Relmada Therapeutics, Inc. (NASDAQRLMD) resulting from allegations that Relmada may have issued materially misleading business information to the investing public.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. (“Relmada” or “the Company”) (NASDAQRLMD) for violations of the securities laws.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. (“Relmada” or “the Company”) (NASDAQRLMD) for violations of the securities laws.
Palm Beach, FL – May 26, 2022 – FinancialNewsMedia.com News Commentary – Worldwide, there is a rapid increase in the prevalence and incidence of neurological disorders such as multiple sclerosis, Alzheimer’s, Parkinson’s, among others. According to Public Health England, the number of individuals with multiple sclerosis has increased over the last few years. This increase […]
Palm Beach, FL –– February 24, 2022 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially but the development of novel medications has not kept pace, precipitating a crisis in psychiatric medicine. A novel innovation is psychedelic drug-assisted psychotherapy – the medically approved use of MDMA, psilocybin, and LSD as […]
Palm Beach, FL –November 23, 2021 – FinancialNewsMedia.com News Commentary – The COVID-19 pandemic is expected to have a significant positive impact on the growth of the global antidepressant market. The pandemic is predicted to have a long and short term impact on the individual’s mental illness, given the hurdles faced during the crisis, such […]
